已收盘 05-22 16:00:00 美东时间
+1.480
+3.62%
今日重点评级关注:Citizens:维持BioCryst制药"跑赢大市"评级,目标价从25美元升至28美元;富国银行:维持曼恩凯德生物医疗"超配"评级,目标价从8美元升至10美元
05-08 12:05
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Advantage Solutions业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **整体表现:** - 净营收7.23亿美元,同比增长4%,剔除资产剥离影响的同比增长4.7% - 调整后EBITDA为6,800万美元,同比增长超过16%,剔除资产剥离影响的同比增长22% - 调整后无杠杆自由现金流7,400万美元,转换率达110% - 季末现金余额1.44亿美元 - 债务减少1.3亿美元,净杠杆率从4.4倍降至4.2倍 **分业务表现:** - **体验服务(Experiential Services):** 营收2.7亿美元,
05-07 12:03
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
Advantage Solutions shares are trading higher after the company reported better...
05-07 01:07
Advantage Solutions (NASDAQ:ADV) reported first-quarter financial results on We...
05-06 21:07
Advantage Solutions (NASDAQ:ADV) reported quarterly losses of $(5.49) per share which missed the analyst consensus estimate of $(3.74) by 46.79 percent. This is a 29.18 percent decrease over losses of $(4.25) per share
05-06 19:06
Blaize Holdings rose 24.3% in pre-market trading on $50M contract with NeoTensr & MOU with Winmate for edge AI deployments. Other gainers & losers.
04-17 17:31
今日重点评级关注:古根海姆:维持Dianthus Therapeutics"买入"评级,目标价从100美元升至200美元;HC Wainwright & Co.:维持Amylyx Pharmaceuticals"买入"评级,目标价从28美元升至34美元
03-05 13:56
Canaccord Genuity analyst Luke Morison maintains Advantage Solutions (NASDAQ:ADV) with a Buy and lowers the price target from $2.5 to $1.5.
03-05 02:56
Advantage Solutions (NASDAQ:ADV) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.03) by 1566.67 percent. This is a 5100 percent decrease over earnings of $0.01 per share
03-03 20:12